Complix Receives €1.9 Million IWT Grant to Accelerate Development Of
Alphabodies™ against Intracellular Disease Targets, Including Cancer
HASSELT, Belgium, October 30, 2012
HASSELT, Belgium, October 30, 2012 /PRNewswire/ --
Complix announces that it has been awarded a €1.9 million grant (approximately
USD$2.4 million) from the Flanders government through IWT (Agency for
Innovation by Science and Technology in Flanders). The grant will allow
Complix to accelerate the development of its unique cell penetrating
Alphabodies (CPABs), against a range of intracellular disease targets,
Alphabodies represent a novel therapeutic development platform with the
potential to address a vast number of disease targets that are currently
considered "undruggable" by the two main classes of therapeutic drugs: small
chemical drugs and therapeutic antibodies. In particular their ability to act
on intracellular protein targets represents a major medical and commercial
During the past year, Complix has generated a wealth of data demonstrating the
attractive properties of CPABs that are capable of acting on intracellular
disease targets. These results show that CPABs are taken up effectively by
tumor cells. Once inside cancer cells the CPABs can act on an oncogenic target
protein and block its function, thereby inducing apoptosis (cell death).
Dr Mark Vaeck, CEO of Complix, said: "We are delighted to have received this
funding from IWT, which is a clear endorsement of the power of our unique CPAB
platform. The results that we have generated so far indicate this platform has
the potential to transform the pharmaceutical industry's ability to address
the most interesting class of potential drug targets, namely intracellular
protein-protein interactions (PPIs).
"Although intracellular PPIs are known to be involved in a variety of
important disease processes, such as cancer, autoimmunity, CNS and metabolic
diseases, most of them have been found intractable by small chemicals or
antibodies. Whilst other new technology platforms are currently also
attempting to address this opportunity, we believe that Complix is well
positioned to become a leading player in this next generation of so called
"cross-over therapeutics", which have the potential to boost future R&D
pipelines and revitalize the growth of the pharmaceutical industry."
Alphabodies are small single chain alpha-helical proteins that are designed by
computer modeling, but are inspired by naturally existing polypeptide
structures. Alphabodies can address a diverse range of traditionally
undruggable disease targets and combine the best beneficial properties of
biologics and small chemical drugs, such as high specificity and potency on
large protein targets, with efficient intracellular penetration and excellent
stability in human serum.
Alphabodies also have the potential to be applied in other fields beyond the
treatment of human disease. Complix recently announced an important
value-generating partnership with Monsanto Company that will apply Complix'
Alphabodies to create novel products for agricultural applications.
Complix discovers and develops Alphabodies, a novel and proprietary class of
biopharmaceuticals that delivers significant advantages over current protein
therapeutic approaches. Alphabodies' most important advantage is their ability
to address currently undruggable extracellular and, in particular,
Complix is developing cell penetrating Alphabodies (CPABs) that have the
potential to modulate intracellular PPIs, and has generated data demonstrating
that CPABs are able to enter cells, bind to disease targets and can generate
biological effects at low concentrations. CPABs have been designed to tackle
the significant proportion of all known human disease targets that are located
inside cells and cannot be addressed by either small chemical drugs or
biologics. These targets belong to the most interesting class of potential
drug targets, namely intracellular protein-protein interactions (PPIs), which
are involved in important disease processes, such as those causing cancer,
CNS, inflammation or metabolic diseases.
Alphabodies are composed of structurally constrained alpha-helical peptide
coils, which make them ideal scaffolds for therapeutic applications as they
combine the specificity of antibodies with small molecule-like properties.
Alphabodies' unique design, which has been invented by the Complix founders,
means that the Company has a unique freedom-to-operate position. Complix has
already established a strong intellectual property position for its Alphabody
platform through the filing of several broad patent applications.
Complix´s current R&D focus is on the development of novel Alphabody-based
therapies for inflammation/autoimmunity and cancer.
Complix raised EUR 7 million through a Series A equity financing round in
2010, with Vesalius Biocapital, LRM and Crédit Agricole Private Equity
(currently Omnes Capital) as the main investors.
Complix is headquartered in Hasselt (Belgium) in the Life Sciences incubator
BioVille, and has research facilities in Ghent (Belgium) and in Luxembourg.
The Company has a fully owned subsidiary in Luxembourg and a strategic
alliance with the public research institute CRP-Santé. For further
information, please visit http://www.complix.com .
Contacts Complix NV Dr. Mark Vaeck, CEO +32-9-261-69-40
Press spacebar to pause and continue. Press esc to stop.